Article
Oncology
Panagiotis A. Konstantinopoulos, Jung-Min Lee, Bo Gao, Rowan Miller, Jung-Yun Lee, Nicoletta Colombo, Ignace Vergote, Kelly M. Credille, Suzanne R. Young, Samuel McNeely, Xuejing Aimee Wang, Aimee Bence Lin, Ronnie Shapira-Frommer
Summary: This study aimed to evaluate the efficacy and safety of using prexasertib, a CHK1 inhibitor, in treating high-grade serous ovarian cancer. The results showed that prexasertib demonstrated durable single agent activity to a certain extent and its effects were not influenced by clinical characteristics, BRCA status, or prior therapies, including PARPi. The study also emphasized the need for alternative biomarker approaches to identify responders.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Chemistry, Medicinal
Qingli Cui, Yanhui Hu, Dongyang Ma, Huaimin Liu
Summary: Anlotinib showed moderate improvements in progression-free survival and overall survival in patients with platinum-resistant or platinum-refractory ovarian cancer, indicating it may be a new treatment option for this group of patients.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Oncology
Madhavi Manyam, Amanda J. Stephens, Jessica A. Kennard, Jane LeBlanc, Sarfraz Ahmad, James E. Kendrick, Robert W. Holloway
Summary: The study demonstrated promising safety, clinical activities, and immune activation of intraperitoneal Olvi-Vec virotherapy in patients with platinum-resistant or refractory ovarian cancer (PRROC), indicating the need for further clinical investigation.
GYNECOLOGIC ONCOLOGY
(2021)
Review
Oncology
Siyu Li, Tao Wang, Xichang Fei, Mingjun Zhang
Summary: Platinum-resistant ovarian cancer is a deadly cancer with a poor prognosis, and ATR inhibitors have shown promising results in its treatment.
Article
Oncology
Rachel E. Kinney, Suresh Nair, Christine H. Kim, M. Bijoy Thomas, Martin DelaTorre
Summary: Platinum-resistant ovarian cancer is associated with poor prognosis and limited treatment options. Combination treatment with immunotherapy, anti-angiogenic therapy, and chemotherapy can significantly extend progression-free survival in these patients.
Article
Oncology
Rachel E. Kinney, Suresh Nair, Christine H. Kim, M. Bijoy Thomas, Martin DelaTorre
Summary: Ovarian cancer is a common gynecologic cancer in the US, and platinum-resistant disease has a poor prognosis. This study suggests that treatment with immunotherapy followed by anti-angiogenic therapy and chemotherapy can improve survival in patients with platinum-resistant ovarian cancer. The experience of three patients showed significantly longer progression-free survival compared to previous averages.
Article
Oncology
Michelle McMullen, Ainhoa Madariaga, Stephanie Lheureux
Summary: Platinum drugs are crucial in ovarian cancer treatment, but resistance is a major challenge, with complex mechanisms involving both intracellular and microenvironment factors. Clinical trials are essential for improving outcomes, and future research should focus on understanding the biology of the disease and enhancing quality of life and survival for patients.
SEMINARS IN CANCER BIOLOGY
(2021)
Review
Oncology
Alice Indini, Olga Nigro, Csongor Gyorgy Lengyel, Michele Ghidini, Angelica Petrillo, Salvatore Lopez, Francesco Raspagliesi, Dario Trapani, Shelize Khakoo, Giorgio Bogani
Summary: Patients with platinum-resistant ovarian cancer have a poor prognosis with limited treatment options. While single-agent immunotherapy has shown disappointing results, combining immunotherapy with target therapies like PARP inhibitors and TKIs appears promising. Ongoing trials are evaluating these combination strategies to assess their impact and cost-effectiveness.
Review
Biochemistry & Molecular Biology
Carolina Maria Sassu, Innocenza Palaia, Serena Maria Boccia, Giuseppe Caruso, Giorgia Perniola, Federica Tomao, Violante Di Donato, Angela Musella, Ludovico Muzii
Summary: Ovarian cancer is the second leading cause of death in women with gynecological cancer, with poor prognosis, especially in platinum-resistant disease. Efforts have been made to define new biomarkers, with circulating biomarkers being detected non-invasively but potentially requiring expensive techniques.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
M. Cummings, C. Freer, N. M. Orsi
Summary: Ovarian cancer often presents at an advanced stage and initial response to platinum-based therapies is positive, but chemoresistance develops leading to poor prognosis. The tumor microenvironment has been found to play a central role in therapy resistance and disease progression, making it an attractive therapeutic target. Focus has been on targeting cancer associated fibroblasts, tumor-associated macrophages, cancer stem cells, and cancer cell metabolic vulnerabilities for new therapies.
SEMINARS IN CANCER BIOLOGY
(2021)
Article
Oncology
Manman Xu, Xi Huang, Cuimiao Zheng, Junming Long, Qingyuan Dai, Yangyang Chen, Jingyi Lu, Chaoyun Pan, Shuzhong Yao, Jie Li
Summary: This study investigates the role of NHEJ in platinum resistance in ovarian cancer and finds that XRCC4 in the NHEJ pathway specifically contributes to resistance by mitigating DNA damage caused by platinum drugs, providing preclinical evidence for targeting XRCC4 as a new strategy to combat cisplatin resistance in ovarian cancer treatment.
Article
Oncology
Francesca Ricci, Alessandro Corbelli, Roberta Affatato, Rosaria Chila, Michela Chiappa, Laura Brunelli, Robert Fruscio, Roberta Pastorelli, Fabio Fiordaliso, Giovanna Damia
Summary: Our study found that acquisition of DDP resistance is associated with morphological alterations in mitochondria, despite the lack of dysregulation in the studied genes/proteins that could explain the observed differences.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Oncology
Mohammad Aslam Khan, Kunwar Somesh Vikramdeo, Sarabjeet Kour Sudan, Seema Singh, Annelise Wilhite, Santanu Dasgupta, Rodney Paul Rocconi, Ajay Pratap Singh
Summary: Resistance to platinum-based chemotherapy in ovarian cancer is a major challenge, with diverse underlying molecular mechanisms complicating management of the disease. Recent research has identified novel molecular targets for treatment planning and monitoring. The therapeutic landscape of ovarian cancer is evolving rapidly, with alternative therapies emerging for recurrent platinum-resistant disease.
SEMINARS IN CANCER BIOLOGY
(2021)
Article
Oncology
Khalid El Bairi, Ouissam Al Jarroudi, Said Afqir
Summary: Platinum-resistant ovarian cancer poses significant challenges in treatment options, with limited therapeutic choices available for patients. The emergence of antibody-drug conjugates (ADCs) provides promising findings for further clinical development in this setting.
SEMINARS IN CANCER BIOLOGY
(2021)
Review
Oncology
Jinbowen Yan, Fangzhi Xu, Dan Zhou, Shuo Zhang, Bo Zhang, Qingwei Meng, Qiubo Lv
Summary: Metabolic reprogramming is the alteration of metabolic pathways in cancer cells to support their growth and survival. Platinum-based chemotherapy resistance is associated with changes in glucose metabolism, amino acid metabolism, fatty acid metabolism, and tricarboxylic acid cycle, leading to the production of metabolic intermediates for cellular component biosynthesis and energy homeostasis.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Dimitrios Nasioudis, Stefan Gysler, Nawar Latif, Lory Cory, Robert L. Giuntoli II, Sarah H. Kim, Fiona Simpkins, Lainie Martin, Emily M. Ko
Summary: The prevalence of ERBB2 gene amplification was investigated among patients with gynecologic malignancies. The study found that ERBB2 amplification is frequently encountered in uterine serous carcinoma and mucinous ovarian carcinoma, but less common in endometrioid endometrial carcinoma.
GYNECOLOGIC ONCOLOGY
(2024)